- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
FIRST: President of India unveils India's home-grown gene therapy for cancer
The President was happy to note that the therapy being launched is the world's most affordable CAR-T cell therapy.
New Delhi: The President of India, Smt Droupadi Murmu has launched India’s first home-grown gene therapy for cancer at IIT Bombay.
Speaking on the occasion, the President said that the launch of India’s first gene therapy is a major breakthrough in our battle against cancer. As this line of treatment, named “CAR-T cell therapy”, is accessible and affordable, it provides a new hope for the whole of humankind. She expressed confidence that it will be successful in giving new lives to countless patients.
The President said that CAR-T cell therapy is considered to be one of the most phenomenal advances in medical science. It has been available in the developed nations for some time, but it is extremely costly, and beyond the reach of most patients around the world. She was happy to note that the therapy being launched is the world’s most affordable CAR-T cell therapy. She said that it is also an example of the ‘Make in India’ initiative; a shining example of the ‘Atmanirbhar Bharat’.
The President was happy to note that India’s first CAR-T cell therapy is developed through collaboration between the Indian Institute of Technology, Bombay and Tata Memorial Hospital in association with industry partner ImmunoACT. She said that this is a praiseworthy example of academia-industry partnership, which should inspire many more similar efforts.
The President said that IIT Bombay is renowned, not only in India but across the world, as a model of technology education. In the development of CAR-T cell therapy, technology is not only being put in the service of humanity, but partnerships have been with an eminent institution from another field as well as with industry. This has been made possible by the focus IIT, Bombay has placed on research and development over the last three decades. She said that with the knowledge base and skills of the faculty and students of IIT Bombay and other similar institutions, India as a whole, would benefit greatly from the technological revolution underway.
Read also: India leads first human clinical trial of gene therapy for haemophilia A: Dr Jitendra Singh
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751